Longitudinal SARS-CoV-2 Nucleocapsid Antibody Kinetics, Seroreversion, and Implications for Seroepidemiologic Studies.
COVID-19
SARS-CoV-2
coronavirus disease
coronaviruses
kinetics
longitudinal
nucleocapsid antibody
respiratory infections
seroepidemiology
seroreversion
severe acute respiratory syndrome coronavirus 2
viruses
zoonoses
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
pubmed:
23
7
2022
medline:
24
8
2022
entrez:
22
7
2022
Statut:
ppublish
Résumé
Given widespread use of spike antibody in generating coronavirus disease vaccines, SARS-CoV-2 nucleocapsid antibodies are increasingly used to indicate previous infection in serologic surveys. However, longitudinal kinetics and seroreversion are poorly defined. We found substantial seroreversion of nucleocapsid total immunoglobulin, underscoring the need to account for seroreversion in seroepidemiologic studies.
Identifiants
pubmed: 35868337
doi: 10.3201/eid2809.220729
pmc: PMC9423917
doi:
Substances chimiques
Antibodies, Viral
0
Coronavirus Nucleocapsid Proteins
0
Phosphoproteins
0
nucleocapsid phosphoprotein, SARS-CoV-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1859-1862Références
MMWR Morb Mortal Wkly Rep. 2022 Apr 29;71(17):606-608
pubmed: 35482574
Nature. 2021 Feb;590(7844):140-145
pubmed: 33137809
Emerg Infect Dis. 2021 Dec;27(12):3020-3029
pubmed: 34477548
Emerg Infect Dis. 2022 Mar;28(3):672-683
pubmed: 35202525
J Appl Lab Med. 2021 Nov 1;6(6):1561-1570
pubmed: 34196711
J Infect. 2021 May;82(5):162-169
pubmed: 33766553